Phenylhexyl isothiocyanate suppresses cell proliferation and promotes apoptosis via repairing mutant P53 in human myeloid leukemia M2 cells

Zou,Yong; Huang,Yiqun; Ma,Xudong

doi:10.3892/ol.2019.10620

Phenylhexyl isothiocyanate suppresses cell proliferation and promotes apoptosis via repairing mutant P53 in human myeloid leukemia M2 cells

Authors:
- Yong Zou
- Yiqun Huang
- Xudong Ma
View Affiliations

Affiliations: Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China
Published online on: July 16, 2019 https://doi.org/10.3892/ol.2019.10620
Pages: 3358-3366

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the specific effect and possible mechanisms of phenylhexyl isothiocyanate (PHI) on cell proliferation and apoptosis in acute myeloid leukemia M2 cell lines. Cell proliferation in several hematological tumor cells lines following PHI treatment was evaluated in vitro using a Cell Counting Kit‑8. The apoptosis and cell cycle of Kasumi‑1 and SKNO‑1 cells (human M2 cell lines) following exposure to PHI were examined using flow cytometry. A colony‑formation assay was used to identify the inhibitory effect of PHI on Kasumi‑1 cells in vitro. Furthermore, Kasumi‑1 xenograft tumor models were established. The antitumor effect of PHI was observed in vivo by measuring the size of the resulting xenograft tumors. The apoptosis of the xenograft tumor cells was measured using a TUNEL assay. Finally, protein expression levels were assessed by western blotting. PHI inhibited cell growth in 16 hematological tumor cell lines, with Kasumi‑1 and SKNO‑1 cells being the most sensitive. In vitro treatment induced apoptosis and inhibited cell cycle arrest at the G0/G1 phase in a dose‑ and time‑dependent manner. PHI also inhibited growth and induced apoptosis in vivo. The compound increased the expression of caspases 3, 9 and 8, Fas and poly (ADP‑ribose) polymerase. Furthermore, PHI enhanced the protein expression of p53, Bax and p21 in a dose‑dependent manner. In conclusion, PHI had a specific and notable inhibitory effect on Kasumi‑1 and SKNO‑1 M2 cell lines in vivo and in vitro. Treatment inhibited cell cycle arrest at the G0/G1 phase, and induced apoptosis through the mitochondrial and Fas death receptor pathways. PHI restored the activity of mutated P53 and reactivated the P53 pathway, highlighting it as a potential target drug for mutated P53.

View Figures

View References

1	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the acute leukaemias French-American-British (FAB) Co-operative Group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
2	Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
3	Dohner H, Weisdorf DJ and Bloomfield CD: Acute Myeloid Leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ferrara F and Del Vecchio L: Acute myeloid leukemia with t(8;21)/AML1/ETO: A distinct biological and clinical entity. Haematologica. 87:306–319. 2002.PubMed/NCBI
5	Isobe M, Emanuel BS, Givol D, Oren M and Croce CM: Localization of gene for human p53 tumour antigen to band 17p13. Nature. 320:84–85. 1986. View Article : Google Scholar : PubMed/NCBI
6	Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
7	Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD: An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA. 95:5166–5171. 1998. View Article : Google Scholar : PubMed/NCBI
8	Carson DA and Lois A: Cancer progression and p53. Lancet. 346:1009–1011. 1995. View Article : Google Scholar : PubMed/NCBI
9	Amundson SA, Myers TG and Fornace AJ Jr: Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene. 17:3287–3299. 1998. View Article : Google Scholar : PubMed/NCBI
10	Kirsch DG and Kastan MB: Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol. 16:3158–3168. 1998. View Article : Google Scholar : PubMed/NCBI
11	Toshinori O and Akira N: Role of p53 in cell death and human cancers. Cancers. 3:994–1013. 2011. View Article : Google Scholar : PubMed/NCBI
12	Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
13	Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K and Neiman RS: Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: An immunohistochemical study of bone marrow biopsies. Mod Pathol. 6:5211993.PubMed/NCBI
14	Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA and Hasserjian RP: High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 28:552–563. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lane DP, Cheok CF and Lain S: p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010. View Article : Google Scholar : PubMed/NCBI
16	Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S and Blandino G: The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle. 7:3440–3447. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L and El-Deiry WS: Small-Molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Res. 75:3842–3852. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chiao JW, Wu H, Ramaswamy G, Conaway CC, Chung FL, Wang L and Liu D: Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis. 25:1403–1408. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lu L, Liu D, Ma X, Beklemishev A, Seiter K, Ahmed T and Chiao JW: The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep. 16:1363–1367. 2006.PubMed/NCBI
20	Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D and Chiao JW: Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 28:1287–1293. 2006.PubMed/NCBI
21	Zhuang Z, Huang Y, Ma X, et al: Histone Methylation and Acetylation Modulated by PHI in Prostate Cancer PC3 Cell Line Acta Medicinae Universitatis Scientiae Et Technologiae Huazhong 06. 2012.
22	Lai YD, Ma XD, Huang YQ, Xu XN, Wang XZ, Chiao DJ and Liu D: Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate. Zhonghua Zhong Liu Za Zhi. 32:8042010.(In Chinese). PubMed/NCBI
23	Jiang S, Ma X, Huang Y, Xu Y, Zheng R and Chiao JW: Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol. 3:482010. View Article : Google Scholar : PubMed/NCBI
24	Yong Z, Ma X, Huang Y, Hong L and Chiao J: Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol. 5:362012. View Article : Google Scholar : PubMed/NCBI
25	Del PG, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, et al: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 101:2125–2131. 2003. View Article : Google Scholar : PubMed/NCBI
26	Redza-Dutordoir M and Averill-Bates DA: Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar : PubMed/NCBI
27	Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D and Ashkenazi A: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 276:466392001. View Article : Google Scholar : PubMed/NCBI
28	Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
29	Shaulsky G, Ben-Ze'Ev A and Rotter V: Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene. 5:1707–1711. 1990.PubMed/NCBI
30	Liao N, Sun L, Chen J, Zhong J, Zhang Y and Zhang R: A novel polysaccharide conjugate from Bullacta exarata induces G1-Phase arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Molecules. 22:3842017. View Article : Google Scholar
31	Parrales A and Iwakuma T: Targeting oncogenic mutant p53 for Cancer Therapy. Front Oncol. 5:2882015. View Article : Google Scholar : PubMed/NCBI
32	Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, et al: Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ. 23:1615–1627. 2016. View Article : Google Scholar : PubMed/NCBI